Plegra

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plegra

Understanding Plegra

Plegra is a pharmacological treatment utilized in the management of specific chronic conditions. It belongs to a class of medications designed to interact with biological pathways to alleviate symptoms or modify the progression of a particular disease state.

Mechanism of Action

The active components in Plegra work by targeting specific receptors or enzymes within the body. By modulating these targets, the medication helps to regulate physiological processes that are otherwise imbalanced. This systemic approach is intended to provide stabilization for patients who have not achieved adequate results through lifestyle modifications or primary therapeutic interventions alone.

Therapeutic Intent

The primary objective of Plegra is to improve the quality of life for individuals dealing with long-term health challenges. It is typically prescribed as part of a comprehensive care plan. The medication is formulated to maintain consistent levels within the bloodstream, ensuring that its therapeutic effects are sustained over time.

Clinical Application

In clinical settings, Plegra is recognized for its specific chemical profile which distinguishes it from other treatments in the same therapeutic category. Its application is determined based on the individual patient's medical history and the specific characteristics of their condition. The focus of the treatment is on long-term management and the reduction of symptom frequency or severity.

Regulatory References

  1. Sildenafil: MedlinePlus Drug Information
  2. Sildenafil - StatPearls - NCBI Bookshelf

What side effects are possible with Plegra?

The safety profile of Plegra, containing Sildenafil, is documented in official regulatory sources like the FDA and EMA. Adverse reactions are classified by frequency and grouped into System-Organ Classes.

Frequency-Classified Adverse Reactions

The most frequent adverse event is headache, which is officially classified as Very Common (ge 1 in 10 patients) in regulatory documents. Common reactions (ge 1 in 100 to <1 in 10 patients) include flushing, dyspepsia (upset stomach), dizziness, and visual color distortions or blurred vision.

Uncommon and Rare events involve effects on several systems, including the nervous, cardiovascular, and ocular systems. Rare, but serious, documented adverse reactions include priapism (a prolonged erection lasting over four hours), sudden vision loss (Non-arteritic Anterior Ischemic Optic Neuropathy, or NAION), and sudden decrease or loss of hearing.

Safety Restrictions and Population-Specific Notes

Contraindications define absolute restrictions on use. Sildenafil is formally contraindicated in patients using nitrate medications (e.g., nitroglycerin) or guanylate cyclase stimulators due to the risk of severe hypotension. It is also contraindicated in individuals with a history of NAION, severe hepatic impairment, or recent stroke or myocardial infarction.

Safety constraints apply to specific populations. Caution is advised for older adults due to potentially reduced drug clearance and for patients with conditions that predispose them to priapism, such as sickle cell anaemia or leukaemia. The regulatory label notes that symptomatic hypotension is most likely to occur within four hours of co-administration with an alpha-blocker. These classifications and restrictions formally structure the official understanding of the medicine’s risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Sildenafil (Plegra) defines overexposure primarily as an escalation of common, dose-related adverse events. Overdose manifestations are associated with an increased incidence and severity of effects such as headache, flushing, dyspepsia, and dizziness, as documented in clinical trial data with high single doses.

Documented Severe Outcomes and Emergency Actions

The most serious documented outcomes requiring immediate attention are related to the drug's vasodilator action. These include severe hypotension (decreased blood pressure), syncope (fainting), and priapism (a painful erection lasting longer than six hours).

Immediate Medical Assistance is Required When:

  • An erection persists for longer than 4 hours. Failure to treat priapism promptly can result in penile tissue damage and permanent loss of potency.
  • A patient experiences a sudden loss of vision in one or both eyes or a sudden decrease or loss of hearing.

Official Management Protocol

In the event of an overdose, no specific antidote is known. Regulatory documents advise that management should involve standard symptomatic and supportive treatment as appropriate for the clinical presentation. Due to the high plasma protein binding of Sildenafil, renal dialysis is not expected to accelerate the clearance of the drug. Official labeling also specifically cautions against using doses higher than recommended in the pediatric population for Pulmonary Arterial Hypertension (PAH), as this was associated with an increase in deaths.

Therapeutic Uses of Plegra

Plegra is commonly used across therapeutic domains where additional symptomatic support is needed, assisting patients who experience symptoms that interfere with daily functioning and overall comfort. The medication is applied across therapeutic domains involving certain distressing symptoms.

It is relevant in contexts marked by increased discomfort related to erectile dysfunction (functional sexual impairment) and supports patients with Pulmonary Arterial Hypertension (PAH). It is applied in addressing conditions where symptoms cluster into a persistent inability to achieve or maintain function, and it is also commonly used to help with symptom groups like excessive fatigue and shortness of breath associated with PAH.

“The core benefit involves providing supportive relief that helps ease the overall symptom burden associated with these clinical manifestations.”

In scenarios related to functional sexual response, Plegra may assist with providing supportive relief when symptoms interfere with routine activities. For PAH patients, it contributes to improved comfort by supporting them during phases of increased distress.


Quick Fact: Supports Functional Stability


Regulatory References

  1. NIH MedlinePlus Drug Information on Sildenafil

Eligibility and Restrictions for Use

The official regulatory profile for Plegra (Sildenafil) strictly defines eligibility based on pre-existing conditions, concomitant medication use, and specific population factors. Adults (age 18 and over) are the approved population for the Erectile Dysfunction (ED) indication.

Absolute Contraindications (Must Not Use)

  • Patients using organic nitrates (e.g., nitroglycerin) or riociguat are absolutely prohibited due to the risk of severe hypotension.
  • Use is contraindicated in patients with known hypersensitivity to Sildenafil.
  • Patients with severe hepatic impairment (Child-Pugh class C), recent history of stroke or myocardial infarction (within six months), or severe hypotension (BP <90/50 mmHg) must not use this medicine.

Age- and Condition-Based Restrictions

  • Geriatric Patients and Organ Impairment: For the ED indication, a lower starting dose (25 mg) is officially recommended for patients 65 years old and those with severe renal impairment or moderate hepatic impairment.
  • Pediatric Use: Plegra is not indicated for individuals under 18 for ED. For Pulmonary Arterial Hypertension (PAH), while approved by the EMA, the FDA recommends against chronic use in children due to clinical trial data suggesting an increased risk of mortality with higher dosages.

Conditions Requiring Caution

Use requires caution in patients with conditions predisposing to priapism (e.g., sickle cell anemia), anatomical deformation of the penis, or certain eye disorders like retinitis pigmentosa.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines known interactions between Plegra (referencing its active component, Niacin) and other medicinal products or substances, as documented in official regulatory labeling. Certain combinations may increase the risk of serious side effects or alter the effectiveness of Plegra or the other drug, necessitating caution and monitoring by a healthcare provider.

Interacting Product Category Potential Interaction Outcome Management Guidance
HMG-CoA Reductase Inhibitors (Statins) Increased risk of muscle toxicity, including myopathy and rhabdomyolysis. Co-administration requires careful consideration and monitoring, especially for high-risk patients.
Bile Acid Sequestrants May significantly decrease the absorption of Plegra. Products like cholestyramine or colestipol should be administered at least four to six hours apart from Plegra.
Antihypertensive Drugs Potential for additive blood pressure lowering effects, leading to hypotension (low blood pressure). Blood pressure should be monitored closely; dose adjustments of antihypertensive medicine may be necessary.

Other products that can cause liver toxicity (hepatotoxic drugs) may increase the risk of liver dysfunction when taken alongside Plegra. Additionally, consuming large quantities of alcohol or hot beverages around the time of dosing may intensify flushing, a common temporary side effect. Diabetic patients should be monitored carefully, as this medication may elevate blood sugar levels, which could impact the required dosage of blood glucose-lowering therapies. The interaction profile is primarily defined by the potential for increased toxicity with other lipid-modifying agents and pharmacokinetic separation requirements for certain drug classes.

Mechanism of Action

The mechanism of Plegra's active ingredient, Sildenafil, is defined by its ability to potentiate a natural biological signal responsible for smooth muscle relaxation. The drug does not initiate the effect but enhances the duration of the body's own chemical response, ensuring the signal is sustained long enough to produce the resultant physiological change.

Inhibition of the PDE5 Enzyme and Signal Preservation

This mechanism centers on the selective inhibition of the Phosphodiesterase type 5 (PDE5) enzyme. By blocking PDE5, the drug prevents the hydrolysis (breakdown) of the crucial intracellular messenger, cyclic Guanosine Monophosphate (cGMP). This preservation of cGMP is the primary molecular action that maintains the chemical signal for muscle relaxation.

Potentiation of the Nitric Oxide/cGMP Cascade

Sildenafil acts only when the Nitric Oxide (NO) pathway is already active (i.e., when an appropriate stimulus is present). NO release triggers the creation of cGMP, and Sildenafil locks this process in place by neutralizing the enzyme (PDE5) that degrades the signal. The mechanism is therefore contingent on the natural physiological pathway for its biochemical operation.

Modulation of Vascular Smooth Muscle Tone

The resulting elevation of cGMP levels leads directly to the sustained relaxation of vascular smooth muscle cells. This effect reduces the tension in the local blood vessel walls, causing vasodilation (widening of the vessels). The physiological consequence is a resultant increase in localized blood perfusion in the affected vascular bed, which serves as the final mechanistic output.

Dosage and Administration Information

How to Use Plegra

Plegra is strictly for oral administration as a tablet and follows two distinct usage patterns based on the intended application: a single-dose, on-demand regimen or a fixed, scheduled maintenance regimen. The administration protocol defines the specific strength and frequency for each pattern.

Usage Pattern Recommended Dosing and Frequency
On-Demand Starting dose is 50 mg, adjustable from 25 mg up to a maximum single dose of 100 mg. Taken as needed, with a maximum frequency of once per day.
Maintenance Recommended dose is 20 mg, taken three times a day (TID), with doses spaced approximately 4 to 8 hours apart.

For on-demand use, the tablet is typically administered approximately one hour before activity. The medication can be taken with or without food, though consuming it with a high-fat meal may delay the onset of action.

Official labeled instructions specify that a lower starting dose of 25 mg is considered necessary for certain populations, including older adults (65 years and over) and patients with severe hepatic or renal impairment. In the maintenance regimen, if a dose is missed, it should be taken as soon as remembered; however, the protocol strictly requires that a double dose must not be taken to compensate for the missed one. The overall protocol structures the use into short-term, event-based support or long-term, routine adherence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Plegra


Evidence for use in Erectile Dysfunction

The clinical research for Sildenafil in adult men with Erectile Dysfunction (ED) primarily utilizes short-term, randomized controlled trials (RCTs), many of which were structured to compare patient groups receiving Sildenafil to groups receiving an inactive substance (placebo). Studies explored outcomes reflecting daily functioning and activity level, focusing on the ability to achieve and maintain an erection sufficient for sexual performance.

Research monitored several types of outcomes related to physical discomfort, including standardized scores on instruments like the International Index of Erectile Function (IIEF). Studies reported measurements of these functional scores; data show patterns related to how the actively studied group compared to the placebo group. The evidence contributes to understanding symptom patterns in conditions marked by functional limitations.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

Research exploring Sildenafil for Pulmonary Arterial Hypertension (PAH) also involved randomized controlled trials to assess its role in conditions marked by functional limitations. Studies focused on outcomes reflecting daily functioning or activity level, primarily by evaluating the Six-Minute Walk Distance (6MWD), a measure of how far a patient can walk in six minutes. Studies also monitored a composite outcome called time to clinical worsening, which tracks major disease progression events.

The trials studied patients who had PAH associated with different causes, and studies monitored changes in their WHO Functional Class, which reflects the intensity of their symptoms like excessive fatigue and shortness of breath. Studies report how symptoms evolved in the observed populations, specifically related to exercise capacity measurements over the short term.

Long-Term Studies and Follow-up

For both indications, the most comprehensive evidence concerning the effectiveness measurements was evaluated in short time intervals, with pivotal trials often lasting just a few months. To better understand the sustained response, researchers conducted long-term extension studies where patients continued observation for periods up to a few years.

However, for both ED and PAH, the long-term effects are not fully established based on the primary efficacy endpoints defined in the initial, short-term regulatory trials. The evidence highlights what is known—and what is still uncertain—about the active component's studied effects over extended periods.

Key Studies & References Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension

Frequently Asked Questions (FAQ)

Common questions about Plegra (FAQ)

Q: What are the most commonly reported side effects of Plegra?

A: According to regulatory documents, the most frequently reported reaction is headache, which is classified as very common. Other common reactions include flushing, dyspepsia (upset stomach), dizziness, and temporary visual color distortions.

Q: Are there any serious side effects associated with taking Plegra?

A: Regulatory sources document rare, but serious, adverse reactions. These include priapism (an erection lasting more than four hours), sudden loss of vision, and a sudden decrease or loss of hearing. Official safety information notes that immediate medical attention is necessary for these reactions.

Q: How does kidney impairment affect the use of Plegra?

A: The regulatory label addresses use in patients with kidney problems. Specifically for the Erectile Dysfunction (ED) indication, the label indicates that use in individuals with severe renal impairment requires dose modification.

Q: Does Plegra have a known interaction with alcohol?

A: Official warnings state that consuming alcohol while taking this medicine may increase the risk of experiencing certain side effects, such as symptoms related to low blood pressure and dizziness. Official warnings state that consulting a healthcare provider about alcohol consumption while taking the medication is necessary.

Q: How quickly should I expect to see an effect from Plegra?

A: The official product information indicates that the active ingredient typically reaches its highest level in the bloodstream within about one hour after the tablet is taken. This timing is what informs expectations regarding when the medicine becomes fully active.

Q: Is Plegra intended for short-term or long-term use?

A: Regulatory documents recognize two distinct usage patterns for this medication. The medication is defined by regulatory agencies as supporting two usage protocols: a single-dose, event-based regimen and a fixed, scheduled maintenance regimen.

Q: What happens if I forget to take Plegra at the usual time?

A: If you are on the maintenance regimen and forget to take a dose, official protocol includes guidance for the maintenance regimen indicating that a dose should be taken as soon as it is remembered. However, the protocol strictly requires that a double dose must never be taken to compensate for a missed dose.

Q: Does Plegra have any known effect on blood pressure?

A: The medication belongs to a class of drugs known as vasodilators, which work by widening local blood vessels. This mechanism causes mild and temporary decreases in blood pressure as an expected pharmacological effect.

Q: Do Plegra side effects generally go away after a few weeks?

A: The experience with the medication indicates that some common side effects may lessen or resolve completely over time. This can happen as the body becomes more adjusted to the medicine during treatment.

Q: Is it possible to have an allergic reaction to Plegra?

A: Yes, official product information confirms that hypersensitivity to the active ingredient is possible. Severe reactions, including anaphylactic shock, have been reported in rare cases following the use of this drug.

Q: What signs might indicate a potentially serious reaction to Plegra?

A: Official product information notes that sudden decrease or loss of vision, sudden hearing loss, or an erection lasting more than four hours are reactions for which immediate medical attention is necessary.

Q: Can Plegra cause weight gain or weight loss?

A: Studies and adverse reaction reports indicate that increased weight is listed as a common side effect, reported by 1% to 10% of patients. No corresponding data on weight loss is consistently reported in the regulatory documents.

Q: What over-the-counter (OTC) medicines are known to interact with Plegra?

A: Official guidance specifically notes that Cimetidine, which is available over-the-counter for stomach acid reduction, may potentially interact with this medication. The label also warns against the use of street drugs that contain nitrates.

Q: Are there any specific foods or drinks that should be avoided with Plegra?

A: Official labeling advises that grapefruit products should be avoided or limited while taking the medication. This is because grapefruit can increase the concentration of the drug in the body and may also delay its onset of action.

Q: Can Plegra be taken at the same time as a multi-vitamin or supplement?

A: The drug label advises patients to inform their healthcare provider of all supplements and vitamins they are taking. This is to ensure all potential interactions are accounted for, as regulatory guidance requires discussion of all supplements with a healthcare provider.

Q: Does Plegra interact with herbal supplements like St. John's Wort?

A: The official labeling specifically includes a warning that the herbal product St. John's Wort may interact with the medication. Official guidance emphasizes the importance of discussing all herbal supplements with a healthcare provider.

Q: What is the duration of effect for a single dose of Plegra?

A: For single-dose administration, the official patient information indicates that the effects of the active ingredient typically last between four to six hours. This time frame describes how long the drug remains active in the body.

Q: What is the regulatory status of Plegra for use in children or adolescents?

A: The drug is not indicated for individuals under 18 for Erectile Dysfunction. For Pulmonary Arterial Hypertension (PAH), the FDA recommends against chronic use in children due to clinical trial data suggesting an increased mortality risk at higher dosages.

Q: What does the official label state about the use of Plegra during pregnancy or breastfeeding?

A: The drug is not indicated for women for ED. If used for the PAH indication, the active ingredient is known to pass into breast milk in tiny amounts, and the regulatory label notes that use in this population involves considering the risks of untreated Pulmonary Arterial Hypertension (PAH) against potential infant exposure.

Q: Is there a risk of dependence or addiction associated with Plegra?

A: No, the drug is not classified as a controlled substance by regulatory bodies like the DEA. This classification is based on the fact that the medication does not produce the psychoactive effects or withdrawal symptoms typically associated with addictive substances.

Q: Is there a generic version of Plegra available?

A: Yes, the active ingredient in this medication, Sildenafil, has approved generic versions recognized by regulatory agencies. Generic versions meet the same high standards of quality and effectiveness as the original compound.

Q: Can Plegra affect my ability to drive or operate machinery?

A: Official warnings note that the presence of vision changes or dizziness may require avoiding driving or operating heavy machinery. This caution is related to the drug's known side effect profile.

Q: Is it normal to feel tired or fatigued when taking Plegra?

A: The official adverse reaction reports list tiredness and difficulty falling asleep (insomnia) as reported side effects associated with the medication.

Q: Can Plegra be taken with acid reflux medications?

A: Regulatory information notes that one type of acid reflux medication, Cimetidine, may potentially interact with this drug. Regulatory guidance emphasizes the importance of a patient’s healthcare provider being informed of all medications, including acid reflux treatments.

Q: Does the medicine need to be kept in the refrigerator?

A: No, the official storage requirement specified by regulatory authorities is Controlled Room Temperature (approximately 20 C–25 C or 68 F–77 F), not refrigeration.

Q: Can Plegra cause changes in mood or behavior?

A: Yes, regulatory documents list mood and behavioral changes as reported side effects. These include anxiety, insomnia (difficulty sleeping), and depression.

How should Plegra be stored and disposed of?

How to Store and Dispose of Plegra

Plegra (sildenafil tablets) must be stored strictly according to regulatory standards to maintain stability and prevent accidental ingestion.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C–25 C or 68 F–77 F).
Protection Keep the medication in its original container, tightly closed, and protected from moisture.
Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Plegra should be discarded using a drug take-back program or an authorized collector as the preferred method. If a program is unavailable, mix the tablets with an undesirable substance (like used coffee grounds or dirt), seal the mixture in a bag, and place it in the household trash. Do not flush this medicine down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plegra found in:

A-Z Index: